What sector does TAIKO PHARMACEUTICAL CO.,LTD. belong to?

TAIKO PHARMACEUTICAL CO.,LTD. operates in the Pharmaceuticals sector, specifically the Pharmaceutical industry, and is listed on the US markets.

What is the current share price of 4574?

As of the latest available quote, 4574 traded at ¥250.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 4574?

TAIKO PHARMACEUTICAL CO.,LTD. has a price-to-earnings (P/E) ratio of about 18.25. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 4574?

The market capitalisation of TAIKO PHARMACEUTICAL CO.,LTD. is approximately ¥12.55B.

Is TAIKO PHARMACEUTICAL CO.,LTD. profitable?

For its latest reported financial year, TAIKO PHARMACEUTICAL CO.,LTD. recorded a net profit margin of about 14.43%.

Does 4574 pay a dividend?

TAIKO PHARMACEUTICAL CO.,LTD. currently has a dividend yield of about 5.49%.

What is the return on equity (ROE) of 4574?

TAIKO PHARMACEUTICAL CO.,LTD. has a return on equity (ROE) of about 11.20%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 4574?

Over the past 52 weeks, 4574 has traded between a low of ¥246.00 and a high of ¥317.00.

TAIKO PHARMACEUTICAL CO.,LTD.

4574 TSE Pharmaceuticals Pharmaceutical

TSE Prime

¥250.00

+0.40%

Delayed · cached 15 min

Fair value analysis

4574

TAIKO PHARMACEUTICAL CO.,LTD.

¥250.00

Close used for this calculation

¥238.40Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

54/100

Profitability8/25

Returns9/25

Balance Sheet21/25

Efficiency16/25

Growth3/25

Good

Quality radar

Consensus fair value

¥238.40

Near FV

▼ -4.6% against the close used

Model range ¥42.07 – ¥367.60

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥42.07Fair value¥238.40Bull¥367.60

FairClose

52-week traded range

52W low ¥247.0052W high ¥316.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

TAIKO PHARMACEUTICAL CO.,LTD. closed at ¥250.00, 4.9% above the consensus fair value of ¥238.40 drawn from 8 valuation models.

Financial DNA score 54/100 — Good. P/E of 13.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

¥195.20

-21.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8%, r=10%, tg=3%, n=10yr

Graham Number

¥265.20

+6.1%

√(22.5 × EPS × BVPS)

EPS=18.38, BVPS=170.07

P/E Fair Value

¥367.60

+47.0%

EPS × 20x (sector P/E)

EPS=18.38, Sector P/E=20x

EV/EBITDA

¥144.17

-42.3%

(EBITDA × 10x − Net Debt) ÷ Shares

EBITDA=724M

Dividend Discount (DDM)

¥42.07

-83.2%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=3.3, r=10%, g=2%

Book Value (P/B)

¥199.22

-20.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=170.07, ROE=11.2%, g=3%, r=10%

Reverse DCF

¥250.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 1.9% | Historical: 0%

Margin of Safety

¥207.00

-17.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=276, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer